Publicacións nas que colabora con JESÚS HERMOSILLA FERNÁNDEZ (11)

2024

  1. Comprehensive physicochemical and functional analysis of pembrolizumab based on controlled degradation studies: Impact on antigen–antibody binding

    European Journal of Pharmaceutics and Biopharmaceutics, Vol. 194, pp. 131-147

2023

  1. Analysing the In-Use Stability of mRNA-LNP COVID-19 Vaccines Comirnaty™ (Pfizer) and Spikevax™ (Moderna): A Comparative Study of the Particulate

    Vaccines, Vol. 11, Núm. 11

  2. Comprehensive physicochemical characterization of a peptide-based medicine: Teduglutide (Revestive®) structural description and stress testing

    European Journal of Pharmaceutics and Biopharmaceutics, Vol. 184, pp. 103-115

2022

  1. Combined use of UV and MS data for ICH Stability-Indication Method: Quantification and isoforms identification of intact nivolumab

    Microchemical Journal, Vol. 182

  2. Comprehensive Analysis of Nivolumab, A Therapeutic Anti-Pd-1 Monoclonal Antibody: Impact of Handling and Stress

    Pharmaceutics, Vol. 14, Núm. 4

  3. Tracking the physicochemical stability of teduglutide (Revestive®) clinical solutions over time in different storage containers

    Journal of Pharmaceutical and Biomedical Analysis, Vol. 221

2021

  1. Stability study over time of clinical solutions of ziv-aflibercept prepared in infusion bags using a proper combination of physicochemical and functional strategies

    Journal of Pharmaceutical and Biomedical Analysis, Vol. 203

  2. The relevance of monoclonal antibodies in the treatment of COVID-19

    Vaccines, Vol. 9, Núm. 6

2020

  1. Comprehensive biophysical and functional study of ziv-aflibercept: characterization and forced degradation

    Scientific Reports, Vol. 10, Núm. 1

  2. Use of subcutaneous tocilizumab to prepare intravenous solutions for COVID-19 emergency shortage: Comparative analytical study of physicochemical quality attributes

    Journal of Pharmaceutical Analysis, Vol. 10, Núm. 6, pp. 532-545

2019

  1. Comparative Stability Studies of Different Infliximab and Biosimilar CT-P13 Clinical Solutions by Combined Use of Physicochemical Analytical Techniques and Enzyme-Linked Immunosorbent Assay (ELISA)

    BioDrugs, Vol. 33, Núm. 2, pp. 193-205